CCA
EWTX icon

Cygnus Capital Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Cygnus Capital Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108 Hold
3,427
– – 0.07% 61
2025
Q4 		$85 Buy
+3,427
New +$68.8K 0.06% 61

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cygnus Capital Advisors's EWTX Position: Q1 2026 in Review

Cygnus Capital Advisors held its Edgewise Therapeutics (EWTX) position steady in Q1 2026 at 3,427 shares worth $108. The position accounts for 0.07% of the portfolio, ranked #61.

Cygnus Capital Advisors first reported a position in EWTX in Q4 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Cygnus Capital Advisors held 3,427 shares of Edgewise Therapeutics worth $108 as of Q1 2026.
  • Cygnus Capital Advisors left its Edgewise Therapeutics share count unchanged in Q1 2026.
  • Edgewise Therapeutics made up 0.07% of Cygnus Capital Advisors's portfolio in Q1 2026, its #61 holding.
  • Cygnus Capital Advisors first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.